Study of 5HT3 and 5HT4 receptors expression in HT29 cell line and human colon adenocarcinoma tissues

Archives of Iranian Medicine

Volumn 13, Issue 2, 2010, Pages 120-125

  Ataee, Ramin ^a   Ajdary, Soheila ^c   Rezayat, Mehdi ^a   Shokrgozar, Mohammad Ali ^c   Shahriari, Shadab ^b   Zarrindast, Mohammad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

5HT3 and 5HT4 receptors; Colon adenocarcinoma; HT29 cell; Serotonin

Indexed keywords

4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 3 PIPERIDINOPROPYL ESTER; AZASETRON; CISAPRIDE; PHENYLBIGUANIDE; SEROTONIN; SEROTONIN 3 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 AGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN 4 RECEPTOR; SEROTONIN ANTAGONIST; 3 (PIPERIDINE 1 YL)PROPYL 4 AMINO 5 CHLORO 2 METHOXYBENZOATE HYDROCHLORIDE; 3-(PIPERIDINE-1-YL)PROPYL 4-AMINO-5-CHLORO-2-METHOXYBENZOATE HYDROCHLORIDE; AMINOBENZOIC ACID DERIVATIVE; BIGUANIDE DERIVATIVE; FUSED HETEROCYCLIC RINGS; OXAZINE DERIVATIVE; PIPERIDINE DERIVATIVE;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CELL ASSAY; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HT29; COLON ADENOCARCINOMA; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; WESTERN BLOTTING; ADENOCARCINOMA; COLON TUMOR; DRUG EFFECT; METABOLISM;

ADENOCARCINOMA; AMINOBENZOIC ACIDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIGUANIDES; BLOTTING, WESTERN; CELL PROLIFERATION; CISAPRIDE; COLONIC NEOPLASMS; HT29 CELLS; HUMANS; OXAZINES; PIPERIDINES; RECEPTORS, SEROTONIN, 5-HT3; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN 5-HT3 RECEPTOR AGONISTS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; SEROTONIN 5-HT4 RECEPTOR AGONISTS; SEROTONIN 5-HT4 RECEPTOR ANTAGONISTS;

EID: 77949411759     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Biasco G, Pantaleo M, Palassini E, Labianca R. Targeted therapy in colorectal cancer: do we know enough? Dig Liver Dis. 2005; 38: 71-77.
2. Warning X, Hani T, Stan Sh. Use of antidepressants and risk of colorectal cancer: a nested case-control study. Lancet Oncol. 2006; 7: 301-308.
3. Yue CT, Liu YL. Fluoxetine increase extracellular levels of 3-methoxy-4-hydroxy phenylglycol in cultured colo320 DM cells. Cell Biochem. 2005; 23: 109-114.
4. Sharpe CR, Collet P, Belzile E, Hanley JA, Boivin JF. The effects of tricyclic antidepressants on breast cancer risk. Br J Cancer. 2002; 86: 92-97.
5. Clark L, Hilakivi WA, Lippman ME. DMBA induced mammary tumor growth in rats exhibiting increased or decreased ability to cope with stress due to early postnatal handling or antidepressant treatment. Physiol. Behav. 1993; 54: 229-236.
6. Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, Gettys TW, et al. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther. 2001; 92: 179-212.
7. Peters JA, Malone HM, Lambert JJ. Recent advances in the electrophysiological characterization of 5HT3 receptors. Trends Pharmacol Sci. 1992; 13: 391-397.
8. Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D. Primary structure and functional expression of the 5HT3receptor, a serotonin-gated ion channel. Science. 1991; 254: 432-437.
9. Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, et al. The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature. 1999; 28: 359-363.
10. Brüss M, Barann M, Hayer-Zillgen M, Eucker T, Göthert M, Bönisch H, et al. Modified 5-HT3A receptor function by co-expression of alternatively spliced human 5-HT3A receptor isoforms. Arch Pharmacol. 2000; 362: 392-401
11. Dumuis A, Bouhelal R, Sebben M, Cory R, Bockaert J. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol Pharmacol. 1988; 34: 880-887.
12. Bockaert J, Fozard JR, Dumuis A, Clarke DE. The 5-HT4 receptor: a place in the sun. Trends Pharmacol Sci. 1992; 13: 141-145.
13. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002; 71: 533-554.
14. Johnson DS, Heinemann SF. Detection of 5-HT3R-A, a 5-HT3 receptor subunit, in submucosal and myenteric ganglia of rat small intestine using in situ hybridization. Neurosci Lett. 1995; 184: 67-70.
15. Nagakura Y, Kontoh A, Tokita K, Tomoi M, Shimomura K, Kadowaki M. Combined blockade of 5-HT3-and 5-HT4-serotonin receptors inhibits colonic functions in conscious rats and mice. J Pharmacol Exp Ther. 1997; 281: 284-290.
16. Siddiqui EJ, Shabbir MA, Mikhailidis DP, Mumtaz, FH, Thompson C. The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. BJU International. 2006; 97: 634-639.
17. Sonier B, Arseneault M, Lavigne C, Ouellette RJ, Vaillancourt C. The 5HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin. Biochem Biophys Res Commun. 2006; 343: 1053-1059.
18. Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, et al. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. The Prostate. 2004; 59: 328-336.
19. Tutton PJ, Barkla DH. The influence of serotonin on the mitotic rate in the colonic crypt epithelium and in colonic adenocarcinoma in rats. Clin Exp Pharmacol Physiol. 1978; 5: 91-94.
20. Tutton PJ, Barkla DH. Evaluation of the cytotoxicity of dihydroxytryptamines and 5-hydroxytryptamine antagonists as cytotoxic agents in dimethylhydrazine-induced adenocarcinomata. Cancer Chemother Pharmacol. 1978; 1: 209-213.
21. Pourgholami MH, Akhter J, Wang L, Lu Y, Morris DL. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2005; 55: 425-432
22. Sonier B, Lavigne C, Arseneault M, Ouellette R, Vaillancourt C. Expression of the 5-HT2A serotoninergic receptor in human placenta and choriocarcinoma cells: mitogenic implications of serotonin. Placenta. 2005; 26: 484-490.
23. Guillet-Deniau I, Burnol AF, Girard J. Identification and localization of skeletal muscle serotonin 5-HT2A receptor coupled to the Jak/STAT pathway. J Biol Chem. 1997; 272: 14825-14829.
24. Grewal JS, Mukhin YV, Garnovskaya MN, Raymond JR, Greene EL. Serotonin 5-HT2A receptor induces TGF-b1 expression in mesangial cells via erk: proliferative and fibrotic signals. Am J Physiol. 1999; 276: 922-930
25. Watts SW, Yang P, Banes AK, Baez M. Activation of erk mitogen activated protein kinase proteins by vascular serotonin receptors. J Cardiovasc Pharmacol. 2001; 38: 539-551.
26. Lefebvre H, Cartier D, Duparc C, Lihrmann I, Contesse V, Delarue C, et al. Characterization of serotonin (4) receptors in adrenocortical aldosterone-producing adenomas: in vivo and in vitro studies. J Clin Endocrinol Metab. 2002; 87: 1211-1216
27. Lambert HW, Lauder JM. Serotonin receptor agonists that increase cyclic AMP positively regulate IGF-I in mouse mandibular mesenchymal cells. Dev Neurosci. 1999; 21: 105-112.
28. Dizeyi N, Bjartell A, Hedlund P, Tasken KA, Gadaleanu V, Abrahamsson PA. Expression of serotonin receptor 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines. Eur Urol. 2005; 47: 895-900.
29. Siddiqui EJ, Shabir M, Mikhailidis DP, Thompson CS, Mumtaz FH. The role of serotonin (5-hydroxytryptamine 1A and 1B) receptors in prostate cancer. J Urol. 2006; 176: 1648-1653